How Biktarvy Works for HIV Infection

Biktarvy is a combination antiretroviral drug used to treat HIV-1 infection. It works by blocking the activity of the HIV protease and integrase enzymes, which are essential for the virus to replicate.

The protease enzyme is responsible for cutting newly synthesized viral proteins into smaller, functional proteins. By blocking the protease, Biktarvy prevents the virus from producing new infectious viral particles.

The integrase enzyme is responsible for inserting the viral DNA into the DNA of the host cell. By blocking the integrase, Biktarvy prevents the virus from integrating its DNA into the host cell's DNA, which is necessary for the virus to replicate.

Biktarvy is typically taken once daily, with or without food. It is available as a tablet that contains bictegravir, emtricitabine, and tenofovir alafenamide.

Biktarvy is a well-tolerated medication, and the most common side effects include nausea, diarrhea, headache, and fatigue. These side effects are usually mild and resolve within a few weeks of starting treatment.

Biktarvy is a highly effective medication for treating HIV-1 infection. In clinical trials, Biktarvy was shown to reduce the amount of HIV in the blood to undetectable levels in over 90% of patients. Biktarvy is also associated with a low risk of developing resistance to the medication.

Biktarvy is a recommended treatment for HIV-1 infection in adults and adolescents aged 12 years and older who weigh at least 35 kg. It is not recommended for use in children under 12 years of age or in pregnant women.